title: Current status of bevacizumab in advanced ovarian cancer.
abstract: Ovarian cancer is the most lethal gynecological cancer, mainly because of the delay in diagnosis. Recently, much effort has been put into investigating and introducing novel targeted agents into clinical practice, with the aim of improving prognosis and quality of life. Angiogenesis is a possible target. The aim of this review is to investigate the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in patients with ovarian cancer. These therapeutic strategies include monoclonal antibodies and tyrosine-kinase inhibitors. These drugs have as molecular targets vascular endothelial growth factor, vascular endothelial growth factor receptors, platelet-derived growth factor, fibroblast growth factor, and angiopoietin. Bevacizumab was investigated in several Phase III studies, with interesting results. Today, there is strong evidence for introducing bevacizumab in the treatment of patients with advanced and recurrent ovarian cancer. Nevertheless, further investigations and large clinical trials are needed to understand the safety and effectiveness of bevacizumab, the optimal duration and timing of treatment, and activity in association with other chemotherapeutic and targeted agents. It also is necessary to identify biologic factors predictive of efficacy to choose the most appropriate antiangiogenic agent in the integrated treatment of epithelial ovarian cancer.
authors.affiliation: Department of Gynaecology and Obstetrics, "Sapienza" University of Rome, Policlinico "Umberto I," Rome, Italy.
authors.forename: Federica
authors.initials: F
authors.lastname: Tomao
authors.forename: Anselmo
authors.initials: A
authors.lastname: Papa
authors.forename: Luigi
authors.initials: L
authors.lastname: Rossi
authors.forename: Davide
authors.initials: D
authors.lastname: Caruso
authors.forename: Pierluigi Benedetti
authors.initials: PB
authors.lastname: Panici
authors.forename: Martina
authors.initials: M
authors.lastname: Venezia
authors.forename: Silverio
authors.initials: S
authors.lastname: Tomao
keywords: angiogenesis; bevacizumab; chemotherapy; epithelial ovarian cancer; vascular endothelial growth factor
references.citation: Gynecol Oncol. 2012 Mar;124(3):563-8
references.pmid: 22138229
references.citation: Crit Rev Oncol Hematol. 2012 Jul;83(1):35-46
references.pmid: 22056314
references.citation: J Clin Oncol. 2012 Jun 10;30(17):2039-45
references.pmid: 22529265
references.citation: Curr Pharm Des. 2007;13(20):2025-44
references.pmid: 17627537
references.citation: Cancer J. 2002 May-Jun;8 Suppl 1:S22-30
references.pmid: 12075699
references.citation: CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
references.pmid: 21685461
references.citation: Eur J Cancer. 2009 May;45(8):1415-23
references.pmid: 19168349
references.citation: Cancer Immunol Immunother. 2004 Mar;53(3):176-86
references.pmid: 14685782
references.citation: J Clin Oncol. 2008 Jan 1;26(1):76-82
references.pmid: 18165643
references.citation: J Clin Oncol. 2010 Jul 1;28(19):3107-14
references.pmid: 20516432
references.citation: J Biol Regul Homeost Agents. 2001 Apr-Jun;15(2):140-4
references.pmid: 11501971
references.citation: J Clin Oncol. 2007 Jul 10;25(20):2894-901
references.pmid: 17617520
references.citation: N Engl J Med. 2012 Mar 29;366(13):1256-7; author reply 1257-8
references.pmid: 22455429
references.citation: Nat Rev Cancer. 2008 Aug;8(8):579-91
references.pmid: 18596824
references.citation: J Clin Oncol. 2014 May 1;32(13):1302-8
references.pmid: 24637997
references.citation: Am J Reprod Immunol. 2005 Dec;54(6):369-77
references.pmid: 16305662
references.citation: J Clin Oncol. 2011 Dec 10;29(35):4662-8
references.pmid: 22067389
references.citation: Am J Pathol. 1995 Jul;147(1):9-19
references.pmid: 7541613
references.citation: Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1789-93
references.pmid: 17009973
references.citation: Gynecol Oncol. 2011 Aug;122(2):350-5
references.pmid: 21546066
references.citation: J Clin Oncol. 2005 Feb 10;23(5):1011-27
references.pmid: 15585754
references.citation: Cancer. 1997 Jul 1;80(1):98-106
references.pmid: 9210714
references.citation: Physiol Rev. 2011 Jul;91(3):1071-121
references.pmid: 21742796
references.citation: Gynecol Oncol. 2006 Nov;103(2):512-7
references.pmid: 16750560
references.citation: Clin Cancer Res. 2007 Jul 15;13(14):4178-84
references.pmid: 17634546
references.citation: Int J Gynecol Cancer. 2005 Jul-Aug;15(4):593-600
references.pmid: 16014111
references.citation: Ann Oncol. 2011 Sep;22(9):2036-2041
references.pmid: 21273348
references.citation: Gynecol Oncol. 2011 Sep;122(3):473-8
references.pmid: 21665250
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2686-91
references.pmid: 19332726
references.citation: Gynecol Oncol. 2011 Apr;121(1):230-8
references.pmid: 21215996
references.citation: Nat Med. 2001 Sep;7(9):987-9
references.pmid: 11533692
references.citation: J Clin Oncol. 2010 Jan 1;28(1):149-53
references.pmid: 19917861
references.citation: J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
references.pmid: 1688381
references.citation: Int J Gynecol Cancer. 2007 Jul-Aug;17(4):771-6
references.pmid: 17343605
references.citation: Gynecol Oncol. 2014 Mar;132(3):517-25
references.pmid: 24476788
references.citation: Science. 2005 Jan 7;307(5706):58-62
references.pmid: 15637262
references.citation: J Hematol Oncol. 2010 Mar 11;3:9
references.pmid: 20222977
references.citation: Anticancer Res. 2004 May-Jun;24(3b):1973-9
references.pmid: 15274387
references.citation: Cancer. 2001 Jan 15;91(2):371-7
references.pmid: 11180084
references.citation: J Immunol. 2005 Jan 1;174(1):215-22
references.pmid: 15611243
references.citation: Nat Rev Cancer. 2002 Oct;2(10):795-803
references.pmid: 12360282
references.citation: Immunology. 2006 Oct;119(2):254-64
references.pmid: 17005005
references.citation: Int J Gynecol Cancer. 2011 Feb;21(2):419-23
references.pmid: 21270624
references.citation: J Clin Oncol. 1991 Oct;9(10):1801-5
references.pmid: 1919630
references.citation: Gynecol Oncol. 2005 Jan;96(1):132-5
references.pmid: 15589591
references.citation: Hum Pathol. 2006 Nov;37(11):1414-25
references.pmid: 17010410
references.citation: Ther Clin Risk Manag. 2009 Aug;5(4):421-6
references.pmid: 19753136
references.citation: Int J Gynecol Pathol. 2007 Oct;26(4):395-403
references.pmid: 17885489
references.citation: N Engl J Med. 2011 Dec 29;365(26):2473-83
references.pmid: 22204724
references.citation: N Engl J Med. 2011 Dec 29;365(26):2484-96
references.pmid: 22204725
references.citation: Lab Invest. 1995 Aug;73(2):213-20
references.pmid: 7637321
references.citation: Cancer Res. 2005 Feb 1;65(3):671-80
references.pmid: 15705858
references.citation: Gynecol Oncol. 2013 Feb;128(2):221-8
references.pmid: 22960352
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5165-71
references.pmid: 18024863
references.citation: Br J Cancer. 2007 Dec 17;97(12):1618-24
references.pmid: 18000504
references.citation: Oncology. 2006;71(1-2):49-53
references.pmid: 17377414
references.citation: Clin Lung Cancer. 2011 May;12(3):143-7
references.pmid: 21663855
references.citation: Anticancer Res. 2006 Sep-Oct;26(5B):3925-32
references.pmid: 17094423
references.citation: Gynecol Oncol. 2004 Sep;94(3):630-5
references.pmid: 15350351
references.citation: Gynecol Oncol. 2003 Sep;90(3):566-71
references.pmid: 13678725
references.citation: Clin Cancer Res. 2002 Oct;8(10):3193-7
references.pmid: 12374688
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: J Clin Oncol. 2008 Dec 10;26(35):5761-6
references.pmid: 19001330
references.citation: Angiogenesis. 2005;8(2):169-82
references.pmid: 16211363
references.citation: Br J Cancer. 2007 Apr 23;96(8):1159-65
references.pmid: 17375046
references.citation: Nat Med. 2003 Jun;9(6):669-76
references.pmid: 12778165
references.citation: Clin Biochem. 2004 May;37(5):363-9
references.pmid: 15087251
references.citation: Gynecol Oncol. 2011 Jul;122(1):111-5
references.pmid: 21497382
references.citation: J Clin Oncol. 2011 Jun 10;29(17):2439-42
references.pmid: 21555691
references.citation: J Clin Oncol. 2009 Mar 20;27(9):1426-31
references.pmid: 19224848
references.citation: Gynecol Oncol. 2009 Mar;112(3):469-74
references.pmid: 19135712
references.citation: N Engl J Med. 2012 Mar 29;366(13):1257; author reply 1258
references.pmid: 22455430
references.citation: Br J Cancer. 2009 Jan 13;100(1):1-7
references.pmid: 19002176
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1867-74
references.pmid: 15774779
references.citation: J Clin Oncol. 2012 Nov 1;30(31):3841-7
references.pmid: 22987083
references.citation: J Clin Oncol. 2013 Jan 1;31(1):166-7
references.pmid: 23169499
references.citation: Gynecol Oncol. 2012 Feb;124(2):205-9
references.pmid: 22044606
references.citation: Gynecol Oncol. 2009 Aug;114(2):195-8
references.pmid: 19447479
references.citation: Nature. 2005 Dec 15;438(7070):967-74
references.pmid: 16355214
references.citation: Anticancer Res. 2013 Mar;33(3):1073-9
references.pmid: 23482784
references.citation: Lancet Oncol. 2012 Dec;13(12):1225-33
references.pmid: 23168362
references.citation: J Clin Oncol. 2010 Jul 1;28(19):3101-3
references.pmid: 20516442
references.citation: Nat Med. 1995 Oct;1(10):1024-8
references.pmid: 7489357
references.citation: Cancer Res. 2006 Dec 15;66(24):11520-39
references.pmid: 17178843
references.citation: Ann Oncol. 2010 Apr;21(4):759-765
references.pmid: 19906760
references.citation: Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun;4(1):26-33
references.pmid: 21833345
references.citation: N Engl J Med. 2012 Mar 29;366(13):1256; author reply 1257-8
references.pmid: 22455428
references.citation: J Clin Oncol. 2010 Jan 1;28(1):154-9
references.pmid: 19917843
references.citation: Cell. 1998 Mar 20;92(6):735-45
references.pmid: 9529250
references.citation: Int J Gynecol Cancer. 2010 Jul;20(5):772-80
references.pmid: 20973267